Life Sciences Review has named Innovations Stem Cell Center (ISCC), led by Bill Johnson, MD, a “Top Stem Cell Therapy Treatments Company” (2025 and 2026) and featured ISCC as the cover story of its annual issue on breakthroughs in regenerative medicine. At a time when many stem cell clinics rely on inconsistent protocols or expensive outsourced biologics, ISCC is charting a new course with a single, standardized, evidence‑based approach. The center uses stem cells derived from a patient’s own adipose tissue — yielding tens of millions of regenerative cells, compared to the thousands typically obtained from bone marrow. This precision reduces costs and complexity while ensuring outcomes are reproducible and backed by rigorous data. “We don’t tell patients anything we cannot back up with research or evidence,” said Bill Johnson, MD, CEO of ISCC. “If we say 83% of patients with knee problems respond to treatment, we can point directly to the supporting data.” Turning Chronic Illness Into Measurable Recovery With more than four decades of medical experience, Dr. Johnson and his team are redefining outcomes for patients once told there were no options beyond symptom management. ISCC’s therapies have delivered remarkable results across conditions once considered irreversible: • Orthopedic Healing: Patients with severe shoulder and knee injuries have regained full mobility within weeks, avoiding surgery and remaining pain‑free for years. • Autoimmune Disorders: Lupus patients have seen painful rashes disappear, and those with scleroderma have regained movement after years of debilitating stiffness. • Neurological Recovery: A factory supervisor with severe neuropathy, unable to walk across the plant floor, regained balance within weeks and returned to work in three months. • Organ Function Restoration: A COPD patient improved lung capacity from 28% to nearly 50%, eliminating frequent hospitalizations. A kidney disease patient told to expect dialysis within five to seven years has maintained normal function for over 20 years. “We’re witnessing the body repair itself in remarkable ways,” Dr. Johnson added. “Our mission is to make this level of recovery possible for as many patients as we can.” A New Standard of Care on the Horizon ISCC’s consistent, data‑driven results have laid the groundwork for Institutional Review Board (IRB)‑approved clinical trials in lupus, chronic kidney disease, and COPD. These trials aim to validate ISCC’s outcomes on a larger scale and integrate stem cell therapy into mainstream practice — potentially transforming care for millions. Medicare spends nearly $40 billion annually on dialysis alone; if early stem cell intervention prevents even half of those cases, the societal impact would be profound.